期刊文献+

胱硫醚-β-合酶(CBS)基因与冠心病发病机制的研究 被引量:12

Relationship between Cystathionine-β-synthase Gene and Pathogenesis of Coronary Heart Disease
下载PDF
导出
摘要 目的 :研究冠心病患者血浆同型半胱氨酸(HCY)水平及HCY代谢相关酶胱硫醚 - β-合酶(CBS)基因T833C位点、G919A位点碱基突变与冠心病的关系。方法 :用酶联免疫试剂盒测定血浆HCY水平 ,采用扩增阻滞突变体系法检测CBS基因中T833C和G919A基因型。结果 :冠心病组HCY水平显著高于对照组(P<0.01)。CBS基因T833C冠心病组CC、CT、TT型频率分布及C、T等位基因频率分布 ,G919A冠心病组AA、AG、GG型频率分布及A、G等位基因频率分布 ,均与对照组有非常显著性差异(P<0.05或P<0.01)。T833C、G919A冠心病组中3种基因型的HCY水平有显著性差异(P<0.05)。冠心病组的CC、CT基因型HCY水平显著高于TT型 ,AA、AG基因型HCY水平显著高于GG型。结论 :(1)高HCY血症是冠心病发病的危险因素 ,CBS基因T833C的CC、CT突变和G919A的AA、AG突变是高HCY血症的原因。(2)CBS基因T833C。 Objective:To study the relationship between cystathionine-β-synthase(CBS)gene and pathoˉgenesis of coronary heart disease(CHD).Methods:Plasma homocystein(HCY)was determined by enzyme linked immunosorbent assay(ELISA)and the mutation of T833C,G919A transition was identified with amˉplification refractory mutation system(ARMS)methods.Results:The mean level of plasma HCY in CHD group was higher than that in control group(P<0.01).In the mutation of T833C and G919A,there were significant differences in the frequences of genotypes and allels of the two groups(P<0.05or P<0.01).There were obˉvious differences in HCY levels among the three genotypes of CBS gene T833C and G919A in CHD group(P<0.05).The plasma HCY levels in CHD group of CC and CT genotypes were much higher than those in TT.Plasma HCY concentrations in CHD patients with homozygosity(AA)and heterozygosity(AG)of G919A mutation were markedly higher than those patients without mutations(GG).Conclusion:(1)Hyperhomocysˉteinemia is an independent risk factor of CHD.CBS is the main enzyme related to homocysteine metabolism.Their genetic mutations are possibly important mechanism of hyperhomocysteinemia.(2)The CBS mutation is related with CHD.
出处 《天津医药》 CAS 北大核心 2003年第3期158-160,共3页 Tianjin Medical Journal
关键词 胱硫醚-β-合酶 基因 冠心病 发病机制 cystathionine beta synthase coronary disease genes cysteine
  • 相关文献

参考文献8

  • 1Bailey LB, Gregory JF.Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: metabolic significance,risk and impact an folate requirement. J Nutr, 1999, 129(5):919~22.
  • 2Rudsum- Hilleland PM.Recent date are not in conflict with homocysteine as a cardiovascular risk factor. Cur Opin Lipidol,1998,9(6): 533~ 9.
  • 3高炜,姜宁,朱国英,孟昭亨,汤键.冠心病患者血浆同型半胱氨酸的变化及其机制的探讨[J].中华医学杂志,1998,78(11):821-823. 被引量:52
  • 4Tsai MY, Garg U, Key NS, et al. Molecular and biochemical approaches in the identification of heterozygous for homocysteinuria. Atherosclerosis, 1996, 122: 69~77.
  • 5Tsai MY,Welge BG, Hanson NQ, et al. Genetic causes of mild hyperhomocysteinemia in patients with premature occlusive coronary artery diseases. Atherosclerosis, 1999, 143(1): 163~70.
  • 6PePe G, Vanegas OC, Rickards O, et al. World distribution of the T 833 C/844 INS 68 CBS in cis double mutation:a reliable anthropological marker. Hum Genet, 1999, 104(2): 126~9.
  • 7Kozich V, Karus E, de Franchis R, et al. Hyperhomocysteinemia in premature arterial disease: examination of cystathionine- β - synthase alleles at the molecular level. Hum Mol Genet, 1995,4(4) :623~9.
  • 8Kluijtmans LA, van den Heuvel LP, Boers GH, et al. Molecular genetic analysis in mild Hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet, 1996, 58( 1 ): 35~ 9.

共引文献51

同被引文献98

引证文献12

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部